233 related articles for article (PubMed ID: 1329478)
41. Assessment of the antihypertensive effect of lisinopril using 24-hour ambulatory monitoring.
Herpin D; Conte D
J Hum Hypertens; 1989 Jun; 3 Suppl 1():11-5. PubMed ID: 2550634
[TBL] [Abstract][Full Text] [Related]
42. Lisinopril: a review of its use in congestive heart failure.
Simpson K; Jarvis B
Drugs; 2000 May; 59(5):1149-67. PubMed ID: 10852646
[TBL] [Abstract][Full Text] [Related]
43. Comparison of the first-dose effect of captopril and lisinopril in heart failure.
Osterziel KJ; Karr M; Busch C; Dietz R
Am J Cardiol; 1992 Oct; 70(10):137C-139C. PubMed ID: 1329469
[No Abstract] [Full Text] [Related]
44. Potential proischemic effect of early enalapril in hypotension-prone patients with acute myocardial infarction. The CONSENSUS II Holter Substudy Group.
Søgaard P; Thygesen K
Cardiology; 1997; 88(3):285-91. PubMed ID: 9129851
[TBL] [Abstract][Full Text] [Related]
45. Safety and efficacy of lisinopril in elderly patients with mild to moderate hypertension.
Marlier R; Vandepapelière P; De Vriese G
J Hum Hypertens; 1989 Jun; 3 Suppl 1():163-7. PubMed ID: 2550639
[TBL] [Abstract][Full Text] [Related]
46. Effects of two different enalapril dosages on clinical, haemodynamic and neurohumoral response of patients with severe congestive heart failure.
Pacher R; Stanek B; Globits S; Berger R; Hülsmann M; Wutte M; Frey B; Schuller M; Hartter E; Ogris E
Eur Heart J; 1996 Aug; 17(8):1223-32. PubMed ID: 8869864
[TBL] [Abstract][Full Text] [Related]
47. Modulation of hemodynamic effects with a converting enzyme inhibitor: acute hemodynamic dose-response relationship of a new angiotensin converting enzyme inhibitor, lisinopril, with observations on long-term clinical, functional, and biochemical responses.
Uretsky BF; Shaver JA; Liang CS; Amin D; Shah PK; Levine TB; Walinsky P; LeJemtel T; Linnemeier T; Rush JE
Am Heart J; 1988 Aug; 116(2 Pt 1):480-8. PubMed ID: 2840815
[TBL] [Abstract][Full Text] [Related]
48. Effects of lisinopril in patients with heart failure and chronic atrial fibrillation.
Van Den Berg MP; Crijns HJ; Van Veldhuisen DJ; Griep N; De Kam PJ; Lie KI
J Card Fail; 1995 Dec; 1(5):355-63. PubMed ID: 12836710
[TBL] [Abstract][Full Text] [Related]
49. Enalapril and lisinopril in renovascular hypertension--antihypertensive and hormonal effects of two new angiotensin-converting-enzyme (ACE) inhibitors. A preliminary report.
Karlberg BE; Fyhrquist F; Grönhagen-Riska C; Tikkanen I; Ohman KP
Scand J Urol Nephrol Suppl; 1984; 79():103-6. PubMed ID: 6089307
[TBL] [Abstract][Full Text] [Related]
50. Enalapril and lisinopril in the treatment of mild to moderate essential hypertension.
Espinel CH; Williams JL; Coughlin SS
Clin Ther; 1990; 12(2):181-90. PubMed ID: 2162258
[TBL] [Abstract][Full Text] [Related]
51. Enalapril in the treatment of mild-to-moderate heart failure in general medical practice: a prospective and multicentre study concerning 17,546 patients.
Messner Pellenc P; Rudnicki A; Leclercq F; Grolleau R
Acta Cardiol; 1995; 50(3):187-201. PubMed ID: 7676758
[TBL] [Abstract][Full Text] [Related]
52. Lisinopril versus slow-release nifedipine in the treatment of mild to moderate hypertension: a multicentre study. The Cooperative Study Group.
Witchitz S; Serradimigni A
J Hum Hypertens; 1989 Jun; 3 Suppl 1():29-33. PubMed ID: 2550643
[TBL] [Abstract][Full Text] [Related]
53. Effect of enalapril on ventricular arrhythmias in congestive heart failure.
Webster MW; Fitzpatrick MA; Nicholls MG; Ikram H; Wells JE
Am J Cardiol; 1985 Sep; 56(8):566-9. PubMed ID: 2994451
[TBL] [Abstract][Full Text] [Related]
54. Comparative effectiveness of enalapril, lisinopril, and ramipril in the treatment of patients with chronic heart failure: a propensity score-matched cohort study.
Fröhlich H; Henning F; Täger T; Schellberg D; Grundtvig M; Goode K; Corletto A; Kazmi S; Hole T; Katus HA; Atar D; Cleland JGF; Agewall S; Frankenstein L; Clark AL
Eur Heart J Cardiovasc Pharmacother; 2018 Apr; 4(2):82-92. PubMed ID: 28475676
[TBL] [Abstract][Full Text] [Related]
55. Lisinopril. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and congestive heart failure.
Lancaster SG; Todd PA
Drugs; 1988 Jun; 35(6):646-69. PubMed ID: 2844497
[TBL] [Abstract][Full Text] [Related]
56. Angiotensin-converting enzyme inhibition and physical training in heart failure.
Meyer TE; Casadei B; Coats AJ; Davey PP; Adamopoulos S; Radaelli A; Conway J
J Intern Med; 1991 Nov; 230(5):407-13. PubMed ID: 1658183
[TBL] [Abstract][Full Text] [Related]
57. Reduction of exercise-induced myocardial ischemia during add-on treatment with the angiotensin-converting enzyme inhibitor enalapril in patients with normal left ventricular function and optimal beta blockade.
van den Heuvel AF; Dunselman PH; Kingma T; Verhorst P; Boomsma F; van Gilst WH; van Veldhuisen DJ
J Am Coll Cardiol; 2001 Feb; 37(2):470-4. PubMed ID: 11216965
[TBL] [Abstract][Full Text] [Related]
58. Neurohormonal activation in patients with acute myocardial infarction or chronic congestive heart failure. With special reference to treatment with angiotensin converting enzyme inhibitors.
Sigurdsson A
Blood Press Suppl; 1995; 1():1-45. PubMed ID: 7599749
[TBL] [Abstract][Full Text] [Related]
59. Duration of angiotensin-converting enzyme inhibition: implications for tolerability.
Murray NH
Cardiology; 1991; 79 Suppl 1():22-9. PubMed ID: 1655262
[TBL] [Abstract][Full Text] [Related]
60. [The value of lysinopril in cardiac insufficiency].
Lambert M; Luccioni R
Rev Prat; 1990 Oct; 40(23 Suppl):53-8. PubMed ID: 2176346
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
